Pfizer Inc. (PFE) Insider Sells $330,000.00 in Stock
Pfizer Inc. (NYSE:PFE) insider Anthony J. Maddaluna sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares in the company, valued at approximately $3,698,871. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Pfizer Inc. (NYSE:PFE) opened at 32.38 on Tuesday. The company has a 50-day moving average of $32.56 and a 200 day moving average of $34.24. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The company has a market capitalization of $196.41 billion, a P/E ratio of 32.51 and a beta of 0.90.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The firm earned $13.05 billion during the quarter, compared to analyst estimates of $13.05 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer’s quarterly revenue was up 7.9% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post $2.41 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.71%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is 106.20%.
Several hedge funds have recently modified their holdings of the company. Franklin Resources Inc. boosted its stake in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. Institutional Capital LLC raised its position in shares of Pfizer by 26.6% in the first quarter. Institutional Capital LLC now owns 579,710 shares of the biopharmaceutical company’s stock worth $17,183,000 after buying an additional 121,960 shares during the period. BlackRock Group LTD raised its position in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the period. BlackRock Fund Advisors raised its position in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares during the period. Finally, Stearns Financial Services Group raised its position in shares of Pfizer by 0.5% in the first quarter. Stearns Financial Services Group now owns 59,093 shares of the biopharmaceutical company’s stock worth $1,752,000 after buying an additional 284 shares during the period. Institutional investors and hedge funds own 69.73% of the company’s stock.
A number of equities analysts have weighed in on PFE shares. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Jefferies Group cut their price target on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, September 13th. Bank of America Corp. set a $40.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 22nd. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $40.00 price target on shares of Pfizer in a research note on Monday, August 22nd. Finally, Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price target on the stock. in a research note on Thursday, October 13th. Thirteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and an average target price of $37.74.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.